DNA Ploidy is an Independent Prognostic Indicator of Overall Survival in Stage I Endometrial Endometrioid Carcinoma

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 5191-5196

  Santala, Markku ^a,b   Talvensaari Mattila, Anne ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

CA 125; DNA ploidy; Endometrial cancer; Flow cytometry; Prognosis; S phase fraction

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; EPIRUBICIN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; ENDOMETRIOID CARCINOMA; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CARCINOMA, ENDOMETRIOID; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0842343487     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD and Karlan BY: HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 85: 729-34, 1995.
2. Rose PG, Reale FR, Beurskens ML and Hunter RE: Preoperative CA-125 levels predict poor prognostic features in early stage, FIGO grade 1 and 2 endometrial adenocarcinoma. Int J Gynecol Cancer 3: 259-63, 1993.
3. Jhala DN, Atkinson BF, Balsara GR, Hernandez E and Jhala NC: Role of DNA ploidy analysis in endometrial adenocarcinoma. Ann Diagn Pathol 5: 267-73, 2001.
4. Kumar D, Dumar S and Lyon D: Comparison of flow cytometric DNA content analysis of fresh and formalin-fixed paraffin-embedded solid neoplasms. Mod Pathol 7: 354-60, 1994.
5. Gudmundsson TE, Hogberg T, Alm P, Anderson H, Baldetorp P, Ferno M, Langstrom E and Killander D: The prognostic information of DNA ploidy and S-phase fraction may vary with histologic grade in endometrial carcinoma. Acta Oncol 34: 803-12, 1995.
6. Susini T, Rapi S, Savino L, Boddi V, Berti P and Massi G: Prognostic value of cytometric deoxyribonucleic acid index in endometrial carcinoma: comparison with other clinical-pathologic parameters. Am J Obstet Gynecol 170: 527-34, 1994.
7. Zaino RJ, Davis AT, Ohlsson-Wilhelm BM and Brunetto VL: DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int J Gynecol Pathol 17: 312-9, 1998.
8. Susini T, Rapi S, Massi D, Savino L, Amunni G, Taddei GL and Massi G: Preoperative evaluation of tumor ploidy in endometrial carcinoma. Cancer 86: 1005-12, 1999.
9. Konski A, Domenico D, Tyrkus M, Irving D, Neisler J, Phibbs G, Zeidner S and Eggleston W: Prognostic characteristics of surgical stage I endometrial adenocarcinoma. Int J Radiat Oncol Biol Phys 35: 935-40, 1996.
10. Mariani L, Conti L, Antenucci A, Vercillo M, Atlante M and Gandolfo GM: Predictive value of cell kinetics in endometrial adenocarcinoma. Anticancer Res 20: 3569-74, 2000.
11. Kaleli S, Kosebay D, Bese T, Demirkiran F, Oz UA, Arvas M, Aydinli K and Erkun E: A strong prognostic variable in endometrial carcinoma: flow cytometric S-phase fraction. Cancer 79: 944-51, 1997.
12. Nordstrom B, Strang P, Bergstrom R, Nilsson S and Tribukait B: A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction. Cancer 78: 1942-51, 1996.
13. Shackney SE and Shankey TV: Common patterns of genetic evolution in human solid tumors. Cytometry 29: 1-27, 1997.
14. Quinn CM and Wright NA: The usefulness of clinical measurements of cell proliferation in gynecological cancer. Int J Pathol 11: 131-43, 1992.
15. Hsieh CH, ChangChien CC, Lin H, Huang EY, Huang CC, Lan KC and Chang SY: Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol 86: 28-33, 2002.
16. Jhang H, Chuang L, Visintainer P and Ramaswamy G: CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. Am J Obstet Gynecol 188: 1195-7, 2003.
17. Santala M, Talvensaari-Mattila A and Kauppila A: Peritoneal cytology and preoperative serum CA 125 level are important prognostic indicators of overall survival in advanced endometrial cancer. Anticancer Res 23: 3097-3104, 2003.
18. Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M and Avinoach I: Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer 12: 372-75, 2002.
19. Zeimet AG, Marth C and Offner FA: Human peritoneal mesothelial cells are more potent than ovarian cells in producing tumor marker CA-125. Gynecol Oncol 62: 384-389, 1996.